p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas

Christopher Gocke, Floyd A. Benko, Michael S. Kopreski, Thomas J. McGarrity

Research output: Contribution to journalArticle

Abstract

Background - A variety of tumor-related DNA has been detected in the plasma and serum of cancer patients, including RAS, the BCL2-IgH transgene, and p53. It is not known whether the APC gene, which is frequently mutated in colorectal cancer (CRC), can be Identified in the plasma of CRC patients. Similarly, it is unknown whether another tumor suppressor gene altered in CRC, p53, is detectable in people with precursor lesions to CRC. Materials and Methods - The plasma of 240 colonoscopy patients was tested for mutations at two frequently altered sites (codons 175 and 248). A restriction enzyme-mediated enrichment assay was used to detect these mutants. We also tested tumor tissue from 8 patients with CRC for mutations in the mutation cluster region of the APC gene using direct DNA sequencing. Corresponding plasma from any positive patient was then similarly sequenced. Results - Three plasma p53 mutations were identified. Two of these patients had adenomas at biopsy, and 1 had a hyperplastic polyp. All were tested for the same p53 mutations, and 1 of the adenomas was positive. One of the 8 CRC patients had a 5-base-pair deletion in the cancer and the same deletion was detectable in that patient's plasma, although at an amount that we estimate at 1-5% of the total APC DNA present. Conclusions - APC mutations are detectable in the plasma of CRC patients. p53 mutants are detectable in the plasma of colorectal adenoma patients. These may have important implications for cancer screening and diagnosis in the large intestine and suggest that all malignant and premalignant DNA alterations from the colon are identifiable in the blood.

Original languageEnglish (US)
Pages (from-to)44-50
Number of pages7
JournalAnnals of the New York Academy of Sciences
Volume906
StatePublished - 2000
Externally publishedYes

Fingerprint

Adenoma
Colorectal Neoplasms
Plasmas
Mutation
Serum
Tumors
Genes
DNA
APC Genes
Neoplasms
Plasma
Cancer
Biopsy
Large Intestine
Assays
Colonoscopy
Screening
Polyps
Tumor Suppressor Genes
Blood

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas. / Gocke, Christopher; Benko, Floyd A.; Kopreski, Michael S.; McGarrity, Thomas J.

In: Annals of the New York Academy of Sciences, Vol. 906, 2000, p. 44-50.

Research output: Contribution to journalArticle

@article{7234ea97732a487b88179626b2c81c45,
title = "p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas",
abstract = "Background - A variety of tumor-related DNA has been detected in the plasma and serum of cancer patients, including RAS, the BCL2-IgH transgene, and p53. It is not known whether the APC gene, which is frequently mutated in colorectal cancer (CRC), can be Identified in the plasma of CRC patients. Similarly, it is unknown whether another tumor suppressor gene altered in CRC, p53, is detectable in people with precursor lesions to CRC. Materials and Methods - The plasma of 240 colonoscopy patients was tested for mutations at two frequently altered sites (codons 175 and 248). A restriction enzyme-mediated enrichment assay was used to detect these mutants. We also tested tumor tissue from 8 patients with CRC for mutations in the mutation cluster region of the APC gene using direct DNA sequencing. Corresponding plasma from any positive patient was then similarly sequenced. Results - Three plasma p53 mutations were identified. Two of these patients had adenomas at biopsy, and 1 had a hyperplastic polyp. All were tested for the same p53 mutations, and 1 of the adenomas was positive. One of the 8 CRC patients had a 5-base-pair deletion in the cancer and the same deletion was detectable in that patient's plasma, although at an amount that we estimate at 1-5{\%} of the total APC DNA present. Conclusions - APC mutations are detectable in the plasma of CRC patients. p53 mutants are detectable in the plasma of colorectal adenoma patients. These may have important implications for cancer screening and diagnosis in the large intestine and suggest that all malignant and premalignant DNA alterations from the colon are identifiable in the blood.",
author = "Christopher Gocke and Benko, {Floyd A.} and Kopreski, {Michael S.} and McGarrity, {Thomas J.}",
year = "2000",
language = "English (US)",
volume = "906",
pages = "44--50",
journal = "Annals of the New York Academy of Sciences",
issn = "0077-8923",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - p53 and APC mutations are detectable in the plasma and serum of patients with colorectal cancer (CRC) or adenomas

AU - Gocke, Christopher

AU - Benko, Floyd A.

AU - Kopreski, Michael S.

AU - McGarrity, Thomas J.

PY - 2000

Y1 - 2000

N2 - Background - A variety of tumor-related DNA has been detected in the plasma and serum of cancer patients, including RAS, the BCL2-IgH transgene, and p53. It is not known whether the APC gene, which is frequently mutated in colorectal cancer (CRC), can be Identified in the plasma of CRC patients. Similarly, it is unknown whether another tumor suppressor gene altered in CRC, p53, is detectable in people with precursor lesions to CRC. Materials and Methods - The plasma of 240 colonoscopy patients was tested for mutations at two frequently altered sites (codons 175 and 248). A restriction enzyme-mediated enrichment assay was used to detect these mutants. We also tested tumor tissue from 8 patients with CRC for mutations in the mutation cluster region of the APC gene using direct DNA sequencing. Corresponding plasma from any positive patient was then similarly sequenced. Results - Three plasma p53 mutations were identified. Two of these patients had adenomas at biopsy, and 1 had a hyperplastic polyp. All were tested for the same p53 mutations, and 1 of the adenomas was positive. One of the 8 CRC patients had a 5-base-pair deletion in the cancer and the same deletion was detectable in that patient's plasma, although at an amount that we estimate at 1-5% of the total APC DNA present. Conclusions - APC mutations are detectable in the plasma of CRC patients. p53 mutants are detectable in the plasma of colorectal adenoma patients. These may have important implications for cancer screening and diagnosis in the large intestine and suggest that all malignant and premalignant DNA alterations from the colon are identifiable in the blood.

AB - Background - A variety of tumor-related DNA has been detected in the plasma and serum of cancer patients, including RAS, the BCL2-IgH transgene, and p53. It is not known whether the APC gene, which is frequently mutated in colorectal cancer (CRC), can be Identified in the plasma of CRC patients. Similarly, it is unknown whether another tumor suppressor gene altered in CRC, p53, is detectable in people with precursor lesions to CRC. Materials and Methods - The plasma of 240 colonoscopy patients was tested for mutations at two frequently altered sites (codons 175 and 248). A restriction enzyme-mediated enrichment assay was used to detect these mutants. We also tested tumor tissue from 8 patients with CRC for mutations in the mutation cluster region of the APC gene using direct DNA sequencing. Corresponding plasma from any positive patient was then similarly sequenced. Results - Three plasma p53 mutations were identified. Two of these patients had adenomas at biopsy, and 1 had a hyperplastic polyp. All were tested for the same p53 mutations, and 1 of the adenomas was positive. One of the 8 CRC patients had a 5-base-pair deletion in the cancer and the same deletion was detectable in that patient's plasma, although at an amount that we estimate at 1-5% of the total APC DNA present. Conclusions - APC mutations are detectable in the plasma of CRC patients. p53 mutants are detectable in the plasma of colorectal adenoma patients. These may have important implications for cancer screening and diagnosis in the large intestine and suggest that all malignant and premalignant DNA alterations from the colon are identifiable in the blood.

UR - http://www.scopus.com/inward/record.url?scp=0034062490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034062490&partnerID=8YFLogxK

M3 - Article

C2 - 10818595

AN - SCOPUS:0034062490

VL - 906

SP - 44

EP - 50

JO - Annals of the New York Academy of Sciences

JF - Annals of the New York Academy of Sciences

SN - 0077-8923

ER -